Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.
Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, Bock HL, Dramé M, Gillard P, Hutagalung Y, Tang H, Teoh YL, Ballou RW; H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand. Chu DW, et al. Vaccine. 2009 Dec 9;27(52):7428-35. doi: 10.1016/j.vaccine.2009.07.102. Epub 2009 Aug 13. Vaccine. 2009. PMID: 19683087 Clinical Trial.
Preliminary findings from the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: a Randomized Controlled Trial.
Cowling BJ, Wong SS, Santos JJS, Touyon L, Ort J, Ye N, Kwok NKM, Ho F, Cheng SMS, Ip DKM, Peiris M, Webby RJ, Wilson PC, Valkenburg SA, Tsang JS, Leung NHL, Hensley SE, Cobey S. Cowling BJ, et al. Among authors: peiris m. medRxiv [Preprint]. 2024 May 17:2024.05.16.24307455. doi: 10.1101/2024.05.16.24307455. medRxiv. 2024. PMID: 38798684 Free PMC article. Preprint.
An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution.
Subissi L, Otieno JR, Worp N, Attar Cohen H, Oude Munnink BB, Abu-Raddad LJ, Alm E, Barakat A, Barclay WS, Bhiman JN, Caly L, Chand M, Chen M, Cullinane A, de Oliveira T, Drosten C, Druce J, Effler P, El Masry I, Faye A, Ghedin E, Grant R, Haagmans BL, Happi C, Herring BL, Hodcroft EB, Ikejezie J, Katawera V, Kassamali ZA, Leo YS, Leung GM, Kondor RJ, Marklewitz M, Mendez-Rico J, Melhem NM, Munster V, Nahapetyan K, Naindoo D, Oh DY, Peacock TP, Peiris M, Peng Z, Poon LLM, Rambaut A, Saha S, Shen Y, Siqueira MM, Volz E, Tessema SK, Thiel V, Triki H, van der Werf S, von Eije K, Cunningham J, Koopmans MPG, von Gottberg A, Agrawal A, Van Kerkhove MD. Subissi L, et al. Among authors: peiris m. Nat Med. 2024 May 8. doi: 10.1038/s41591-024-02949-0. Online ahead of print. Nat Med. 2024. PMID: 38720002 No abstract available.
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Cheng SMS, Mok CKP, Li JKC, Chan KKP, Luk KS, Lee BHW, Gu H, Chan KCK, Tsang LCH, Yiu KYS, Ling KKC, Tang YS, Luk LLH, Yu JKM, Pekosz A, Webby RJ, Cowling BJ, Hui DSC, Peiris M. Cheng SMS, et al. Among authors: peiris m. Virol J. 2024 Mar 21;21(1):70. doi: 10.1186/s12985-024-02335-9. Virol J. 2024. PMID: 38515117 Free PMC article.
383 results